Who should be really considered as a poor mobilizer in the plerixafor era?

Giovanna Andreola, Anna Vanazzi, Davide Radice, Aleksandra Babic, Cristina Rabascio, Mara Negri, Giovanni Martinelli, Daniele Laszlo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients with a number of peripheral CD34+ cells ≤20/μL have recently been defined in the literature as "poor mobilizers". We retrospectively reviewed medical records from a total of 248 patients affected by hematological malignancies or solid tumors undergoing peripheral blood stem cell collection following chemotherapy plus G-CSF. On the basis of the CD34+ cell peak in peripheral blood following mobilization therapy, patients were defined as good mobilizers (group A, CD34+ cells ≥20/μL), relative poor mobilizers (group B, CD34+ cells 6 CD34+cells/kg for each transplantation procedure. All patients in group A, 20 patients in group B (57%) and 1 patient in group C (2.7%) were able to collect ≥2.0×10 6 CD34+cells/kg. The multivariate analysis confirmed that more than three lines of previous chemotherapy and a previous autologous PBSC transplantation negatively affect mobilization of CD34+ cells in peripheral blood. Our data suggest that a number of CD34+ cells ≤20/μL does not always result in a failed stem cell collection and in fact in our patient series more than 70% of the patients defined as poor mobilizers have indeed collected the minimum number of 2.0×10 6 CD34+cells/kg required for a successful transplantation. The use of new agent such as CXCR4 antagonist plerixafor might further improve mobilization efficacy in such patients.

Original languageEnglish
Pages (from-to)27-32
Number of pages6
JournalTransfusion and Apheresis Science
Volume47
Issue number1
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Transplantation
JM 3100
Drug Therapy
Autologous Transplantation
Granulocyte Colony-Stimulating Factor
Hematologic Neoplasms
Medical Records
Stem Cells
Multivariate Analysis
Cell Count
Neoplasms
Therapeutics
Peripheral Blood Stem Cells

Keywords

  • CD34+ cells
  • Poor mobilizers
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology

Cite this

Who should be really considered as a poor mobilizer in the plerixafor era? / Andreola, Giovanna; Vanazzi, Anna; Radice, Davide; Babic, Aleksandra; Rabascio, Cristina; Negri, Mara; Martinelli, Giovanni; Laszlo, Daniele.

In: Transfusion and Apheresis Science, Vol. 47, No. 1, 08.2012, p. 27-32.

Research output: Contribution to journalArticle

@article{2c551feebbfb43f7b9aea94218578d0a,
title = "Who should be really considered as a poor mobilizer in the plerixafor era?",
abstract = "Patients with a number of peripheral CD34+ cells ≤20/μL have recently been defined in the literature as {"}poor mobilizers{"}. We retrospectively reviewed medical records from a total of 248 patients affected by hematological malignancies or solid tumors undergoing peripheral blood stem cell collection following chemotherapy plus G-CSF. On the basis of the CD34+ cell peak in peripheral blood following mobilization therapy, patients were defined as good mobilizers (group A, CD34+ cells ≥20/μL), relative poor mobilizers (group B, CD34+ cells 6 CD34+cells/kg for each transplantation procedure. All patients in group A, 20 patients in group B (57{\%}) and 1 patient in group C (2.7{\%}) were able to collect ≥2.0×10 6 CD34+cells/kg. The multivariate analysis confirmed that more than three lines of previous chemotherapy and a previous autologous PBSC transplantation negatively affect mobilization of CD34+ cells in peripheral blood. Our data suggest that a number of CD34+ cells ≤20/μL does not always result in a failed stem cell collection and in fact in our patient series more than 70{\%} of the patients defined as poor mobilizers have indeed collected the minimum number of 2.0×10 6 CD34+cells/kg required for a successful transplantation. The use of new agent such as CXCR4 antagonist plerixafor might further improve mobilization efficacy in such patients.",
keywords = "CD34+ cells, Poor mobilizers, Stem cell mobilization",
author = "Giovanna Andreola and Anna Vanazzi and Davide Radice and Aleksandra Babic and Cristina Rabascio and Mara Negri and Giovanni Martinelli and Daniele Laszlo",
year = "2012",
month = "8",
doi = "10.1016/j.transci.2012.03.004",
language = "English",
volume = "47",
pages = "27--32",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Who should be really considered as a poor mobilizer in the plerixafor era?

AU - Andreola, Giovanna

AU - Vanazzi, Anna

AU - Radice, Davide

AU - Babic, Aleksandra

AU - Rabascio, Cristina

AU - Negri, Mara

AU - Martinelli, Giovanni

AU - Laszlo, Daniele

PY - 2012/8

Y1 - 2012/8

N2 - Patients with a number of peripheral CD34+ cells ≤20/μL have recently been defined in the literature as "poor mobilizers". We retrospectively reviewed medical records from a total of 248 patients affected by hematological malignancies or solid tumors undergoing peripheral blood stem cell collection following chemotherapy plus G-CSF. On the basis of the CD34+ cell peak in peripheral blood following mobilization therapy, patients were defined as good mobilizers (group A, CD34+ cells ≥20/μL), relative poor mobilizers (group B, CD34+ cells 6 CD34+cells/kg for each transplantation procedure. All patients in group A, 20 patients in group B (57%) and 1 patient in group C (2.7%) were able to collect ≥2.0×10 6 CD34+cells/kg. The multivariate analysis confirmed that more than three lines of previous chemotherapy and a previous autologous PBSC transplantation negatively affect mobilization of CD34+ cells in peripheral blood. Our data suggest that a number of CD34+ cells ≤20/μL does not always result in a failed stem cell collection and in fact in our patient series more than 70% of the patients defined as poor mobilizers have indeed collected the minimum number of 2.0×10 6 CD34+cells/kg required for a successful transplantation. The use of new agent such as CXCR4 antagonist plerixafor might further improve mobilization efficacy in such patients.

AB - Patients with a number of peripheral CD34+ cells ≤20/μL have recently been defined in the literature as "poor mobilizers". We retrospectively reviewed medical records from a total of 248 patients affected by hematological malignancies or solid tumors undergoing peripheral blood stem cell collection following chemotherapy plus G-CSF. On the basis of the CD34+ cell peak in peripheral blood following mobilization therapy, patients were defined as good mobilizers (group A, CD34+ cells ≥20/μL), relative poor mobilizers (group B, CD34+ cells 6 CD34+cells/kg for each transplantation procedure. All patients in group A, 20 patients in group B (57%) and 1 patient in group C (2.7%) were able to collect ≥2.0×10 6 CD34+cells/kg. The multivariate analysis confirmed that more than three lines of previous chemotherapy and a previous autologous PBSC transplantation negatively affect mobilization of CD34+ cells in peripheral blood. Our data suggest that a number of CD34+ cells ≤20/μL does not always result in a failed stem cell collection and in fact in our patient series more than 70% of the patients defined as poor mobilizers have indeed collected the minimum number of 2.0×10 6 CD34+cells/kg required for a successful transplantation. The use of new agent such as CXCR4 antagonist plerixafor might further improve mobilization efficacy in such patients.

KW - CD34+ cells

KW - Poor mobilizers

KW - Stem cell mobilization

UR - http://www.scopus.com/inward/record.url?scp=84862883674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862883674&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2012.03.004

DO - 10.1016/j.transci.2012.03.004

M3 - Article

VL - 47

SP - 27

EP - 32

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 1

ER -